Amedisys Reports First Quarter 2019 Financial Results and Reaffirms 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amedisys (AMED) PT Raised to $127 at Craig-Hallum
May 1, 2019 3:28 PM EDTCraig-Hallum analyst Kevin Ellich raised the price target on Amedisys (NASDAQ: AMED) to $127.00 while maintaining a Hold rating following results.
Strong start to the yearmargin expansion to slow before picking back up due to CCH acquisition... MoreAmedisys (AMED) Tops Q1 EPS by 21c, Offers FY Guidance
April 30, 2019 4:37 PM EDTAmedisys (NASDAQ: AMED) reported Q1 EPS of $1.11, $0.21 better than the analyst estimate of $0.90. Revenue for the quarter came in at $467.3 million versus the consensus estimate of $460.61 million.
GUIDANCE:
Amedisys sees FY2019 EPS of $3.98-$4.09, versus the consensus of $4.02. Amedisys sees... More
